THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 122 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,965,580 | -10.1% | 459,511 | +7.8% | 0.00% | 0.0% |
| Q2 2023 | $4,413,447 | +231.3% | 426,420 | +247.3% | 0.00% | 0.0% |
| Q1 2023 | $1,332,011 | -18.8% | 122,766 | -16.0% | 0.00% | 0.0% |
| Q4 2022 | $1,639,848 | -14.9% | 146,154 | -23.1% | 0.00% | 0.0% |
| Q3 2022 | $1,926,000 | +145.0% | 189,947 | +119.0% | 0.00% | – |
| Q2 2022 | $786,000 | -82.8% | 86,733 | -81.8% | 0.00% | -100.0% |
| Q1 2022 | $4,565,000 | +675.0% | 477,434 | +796.3% | 0.00% | – |
| Q4 2021 | $589,000 | +450.5% | 53,266 | +268.7% | 0.00% | – |
| Q3 2021 | $107,000 | -63.1% | 14,446 | +1.8% | 0.00% | – |
| Q1 2021 | $290,000 | -7.3% | 14,192 | -32.9% | 0.00% | – |
| Q3 2020 | $313,000 | -98.8% | 21,140 | -98.3% | 0.00% | -100.0% |
| Q2 2020 | $25,585,000 | +646.6% | 1,218,912 | +762.5% | 0.02% | +111.1% |
| Q1 2018 | $3,427,000 | +1622.1% | 141,329 | +1235.3% | 0.01% | +800.0% |
| Q1 2016 | $199,000 | – | 10,584 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Woodford Investment Management Ltd | 11,213,879 | $254,331,000 | 30.84% |
| Cormorant Asset Management, LP | 1,300,000 | $29,484,000 | 2.18% |
| Baupost Group | 9,309,168 | $211,132,000 | 1.85% |
| SENZAR ASSET MANAGEMENT, LLC | 27,397 | $621,000 | 1.79% |
| ARMISTICE CAPITAL, LLC | 1,180,000 | $26,762,000 | 1.75% |
| Old West Investment Management, LLC | 111,101 | $2,519,000 | 1.27% |
| Chescapmanager LLC | 403,321 | $9,147,000 | 1.06% |
| Virtus ETF Advisers LLC | 30,055 | $682,000 | 0.60% |
| Rock Springs Capital Management LP | 652,600 | $14,801,000 | 0.57% |
| Foundation Asset Management, LP | 27,154 | $616,000 | 0.53% |